Drug Trial Radar · NCT07006805
RESET-MS: A Study to Evaluate the Safety and Efficacy of CABA-201 in Participants With Multiple Sclerosis
Last checked: Nov 19, 2026Latest source record: Jun 25, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Withdrawn
Enrollment
0
Actual
Start
Jun 2026
Primary completion
Sep 2028
Study completion Oct 2029
Sponsor
- Lead sponsor
- Cabaletta BioIndustry
- Sponsor type
- Industry
- First posted
- Jun 5, 2025
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Non randomized
- Model
- Sequential
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 60 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
RESET-MS: A Phase 1/2 Open-Label Study to Evaluate the Safety and Efficacy of Autologous CD19-specific Chimeric Antigen Receptor T cells (CABA-201) in Participants with Multiple Sclerosis
Conditions
- Relapsing Multiple Sclerosis (RMS)
- Progressive Multiple Sclerosis (PMS)
- Multiple Sclerosis - Relapsing Remitting
- Multiple Sclerosis
- Multiple Sclerosis (Relapsing Remitting)
- Multiple Sclerosis (MS) - Relapsing-remitting
- Progressive Multiple Sclerosis
Interventions
CABA-201Biological
Single intravenous infusion of CABA-201 following preconditioning with fludarabine and cyclophosphamide
Primary outcomes
What the sponsor says the trial is designed to measure.
- Primary (Part A: Dose Escalation) incidence and severity of adverse eventsTime frame: Up to 28 days after CABA-201 infusion
- Primary (Part B: Dose Expansion) incidence of and severity of adverse events in order to confirm the dose(s) of CABA-201Time frame: Up to 28 days after CABA-201 infusion
Locations
No sites are listed on the registry yet.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.